Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds of Formula II in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases. wherein X is S, N, O or CR; Y is CRR?, O, NR6, CRR?—CRR? or CR?CR; Z is NR6, O, S, CRR? or CRR?—CRR?; R1-R3 are independently selected from the group consisting of H, C1-C8 alkyl, C1-C8 alkoxy, amino, hydroxy, halosubstituted alky and halo; R4 is Q is CR, NR6 or R5 is H or benzyl; R6 is H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo; and R and R? are independently H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a polymer material having a carrier transport property. The polymer material has first and second states in which degrees of the carrier transport property are different from each other, microscopic structures in the first and second states are different from each other, and one of the first and second states can be changed into the other state.

Abstract: This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.

Abstract: A mixture of isolated or synthetic affinity molecules in a liquid carrier is disclosed. The mixture comprises at least two different affinity molecules, each with affinity for a predetermined analyte, for use in a single or multi flow cell piezoelectric crystal micro balance apparatus. Each isolated or synthetic affinity molecule forms together with the predetermined analyte an interaction pair selected from the group consisting of anion-cation, antibody-antigen, receptor-ligand, enzyme-substrate, oligonucleotide-oligonucleotide with complementary sequence, oligonucleotide-protein, oligonucleotide-cell, and peptide nucleic acid (PNA) oligomer-polynucleotide, wherein the polynucleotide may be selected from the group consisting of RNA, DNA and PNA polymers complementary to PNA oligomer. Use of the mixture for introduction into the liquid flow of a single or multi flow cell piezoelectric crystal micro balance apparatus is also described, as well as a kit containing the mixture.

Abstract: An ink jet recording material free of blotting when printed in dye ink and pigment ink, superior in print density and permitting clear printing of a high-definition image is disclosed. The ink jet recording material comprises a substrate at least one surface of which is treated with an ink fixing agent, the ink fixing agent being a cationic surfactant represented by the following general formula: where R is an alkyl group having 8 to 18 carbon atoms.

Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula where Z1 and Z2 comprise, each independently, a bond, a vinyl group, a —CR1?N—NR2— group, or a —CR3?N—N?CR4— group; Y1 and Y2 comprise, each independently, an aromatic group; X1 and X2 are, each independently, a linking group; W1 and W2 are, each independently, a —(CH2)n— group or a —(CH2)n-1—C(?O)— group, where n is an integer between 1 and 10, inclusive; Q1 and Q2 are, each independently, O, S, or NR; and R1, R2, R3, R4, R, R?, and R? comprise, each independently, H, an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a heterocyclic group, or an aromatic group; and (b) a charge generating compound. Corresponding electrophotographic apparatuses and imaging methods are described.

Abstract: This invention relates to novel phenylbenzamides of the formula (I) in which R1 represents trifluoromethyl, chlorine, bromine or iodine and R2 represents hydrogen, methyl or ethyl, to a process for preparing these substances and their use for controlling unwanted microorganisms, and to novel intermediates and their preparation.

Abstract: A method for the selective reduction of an aromatic compound. The present invention provides a method for pre-venting the reduction of at least one halogen substituted aromatic ring of an aromatic compound, while allowing the reduction of at least one functional group on the aromatic compound. In the present invention at least one hydroxyl group is placed on the at least one halogen substituted aromatic ring to be protected from reduction. The aromatic compound is then reacted with at least one alkali metal in at least one nitrogen containing base and at least one alcohol at a ratio of the alcohol to the nitrogen containing base at which the aromatic ring with the hydroxyl group is protected from reduction, while the desired functional group is reduced.

Abstract: An object of the present invention is to provide a modified cyclic aliphatic polyamine having a low viscosity and a small content of unreacted polyamine which can provide, when it is used as a curing agent for epoxy resin, an epoxy resin composition having an improved workability without adding solvent or diluent and an excellent property of epoxy resin cure product. The above modified cyclic aliphatic polyamine is obtained by addition reaction of a cyclic aliphatic polyamine such as isophoronediamine and norbornanediamine and an alkenyl compound such as styrene. The modified cyclic aliphatic polyamine thus obtained is added in epoxy resin to be used as a curing agent for epoxy resin.

Abstract: This invention provides O-?-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimehtylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): wherein the variables R1 and R2 are defined herein, and where the configuration at the steriogenic center (*) may be R, S, or RS (the racemate).

Abstract: The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.

Abstract: A compound of formula (I), where x is 3, 2 or 1, y is 0 or 1, n1 and n2, which may be the same or different, are 0 or 1 to 3, X represents a divalent mono- or poly-aromatic and/or heteroaromatic moiety, the or each Y, which may be the same or different if x is 1, represents hydrogen or an optionally substituted hydrocarbon group, Z represents an aromatic group, or an inherently at least partly conjugated dendritic molecular structure comprising one or more aromatic and/or heteroaromatic groups and, optionally, alkenylene groups, connected to each other either directly or via a carbon atom of an alkenylene group, if present, to a ring carbon atom of an (hetero) aromatic group to which more than one at least partly conjugated dendritic chain is attached, said molecular structure being connected to the remainder of the molecule via a ring carbon atom, one or more of the (hetero) aromatic rings of the dendrimers optionally being substituted, Z and/or the remainder of the molecule, excluding any groups Y, bein

Abstract: The present invention is related to an intermediate layer of an organic electroluminescent device comprising an amine derivative substance which may further comprise a functional group capable of forming crosslinks. In particular, the substance may have excellent solubility and can be easily formed into a thin film. Specifically, the thin film may be stable in the solvent and can be easily formed to various thicknesses. Furthermore, the band gaps and LUMO/HOMO values may be easily controlled depending of the characteristics of the hole transporting material, so that an intermediate layer with the desired characteristics may be formed. Accordingly, the introduction of an intermediate layer manufactured using the substance of the present invention as the intermediate layer may result in an organic electroluminescent device having high efficiency and a longer lifespan.

Abstract: A process for preparing indanylamine and aminotetralin derivatives from indanone or tetralone oximes by acylating the oximes with an organic anhydride, followed by catalytic hydrogenation in the presence of an organic anhydride with subsequent hydrolysis is described. The process is commercially feasible providing indanylamine and aminotetralin derivatives in high yield that are useful as intermediates in the production of therapeutically active compounds. Also described are novel intermediates, 1-indanone O-acetyl oximes and 1-tetralone O-acetyl oximes.

Abstract: The present invention relates to red color emitting compounds for an organic electroluminescent device (OELD), particularly to red color emitting compounds represented by the following formula (1) having high luminescence efficiency and enhanced thermal-stability: R1—CH?CH—X—CH?CH—R2 wherein, R1, R2 and X each are as defined below.

Abstract: Compounds of formula I: where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X is CH2, O or S, and n is 1, 2 or 3, with the proviso that if X is CH2, n is not 1, and a method for their preparation. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Abstract: The invention provides sodium channel modulating compounds which are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. The invention also provides pharmaceutical compositions comprising a compound of the present invention, as well as therapeutic methods comprising administering such a compound or salt to a mammal (e.g. a human).

Abstract: Disclosed are multibinding compounds which are ?2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: Disclosed herein is a process for the preparation of alkylated diarylamines comprising adding to said diarylamine an olefin mixture containing highly reactive fractions, as well as fractions exhibiting a relatively lower chemical reactivity, in the presence of an acidic clay catalyst at a temperature low enough to prevent substantial deactivation of the catalyst until the addition is complete and then increasing the temperature to increase the alkylation rate of the less reactive fractions.

Abstract: Arylamine derivatives that can be utilized as hole transport or hole injection materials of organic electroluminescence devices, electrophotographic reactors, etc., and synthetic intermediates thereof, and processes of producing those. The arylamine derivative is represented by the general formula (1): wherein R1 to R4 each independently represents a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, an aryloxy group, a halogen atom, an amino group, etc.; Ar1 and Ar2 each independently represents a substituted or unsubstituted aryl group or hetero-aromatic group, and Ar1 and Ar2 may form a nitrogen-containing heterocyclic ring together with the nitrogen atom to which Ar1 and Ar2 bond; and Ar3 represents a substituted or unsubstituted arylene group.

Abstract: A compound of Formula (IA) or Formula (IB) wherein R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Abstract: A process for the preparation of substituted halogenated anilines from substituted halogenated 1-chlorobenzenes which comprises a) reacting a substituted halogenated 1-chlorobenzene selectively with an imine in the presence of a transition metal catalyst complex and a base to form an N-aryl imine; b) hydrolyzing the N-aryl imine; and c) isolating the substituted halogenated aniline.

Abstract: This patent discloses a substituted fullerenes, compositions comprising the same, and their use as antioxidants. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 —X3 groups bonded to the fullerene core; (iii) from 1 to 6 —X4— groups bonded to the fullerene core; or (iv) from 1 to 6 dendrons bonded to the fullerene core.

Abstract: The invention relates to chiral Mannich bases of formula (I), chiral 1,3-amino alcohols of formula (II) derived therefrom, wherein R1, R2, R3, R4 and R5 are as defined herein, and to processes for preparing Mannich salts of formula (III) containing a chiral anion Y*? and compounds of formulae (I) and (II), wherein R1, R2, R3, R4, R5 and Y*? are as defined herein.

Abstract: This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)— and (S)— forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)— or (S)— enantiomer of primary amino-substituted fused bicyclic ring systems.

Abstract: New ligands and compositions with bridged bis-aromatic ligands are disclosed that catalyze the polymerization of monomers into polymers. These catalysts with metal centers have high performance characteristics, including higher comonomer incorporation into ethylene/olefin copolymers, where such olefins are for example, 1-octene, propylene or styrene. The catalysts also polymerize propylene into isotactic polypropylene.

Abstract: A method for bisformylation an arylamine compound by reacting an arylamine compound with an alkyleneamine in a reaction mixture while refluxing an acid in the reaction mixture.

Abstract: Multiphasic reactions, especially those reactions using a phase transfer catalyst, are conducted in microchannel apparatus. Advantageously, these reactions can be conducted with two, planar microlayers of reactants in adjacent laminar flow streams. Microchannel apparatus and methods for conducting unit operations such as reactions and separations in microchannel apparatus is also described. Microchannel apparatus can provide advantages for controlling reactions and separating products, solvents or reactants in multiphase reactions.

Abstract: Disclosed are multibinding compounds which are ?2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: This application relates to a new process for the production of R-phenylacetylcarbinol by an enzymatic process in a liquid two-phase system.

Abstract: This invention relates to apparatus particularly a monolith catalytic reactor in a stirred tank reactor. The stirred tank reactor including the fixed bed catalytic reactor apparatus comprises: an housing having an open top and open bottom portion supportably maintained with said tank, said housing having a substantially outwardly extending, horizontal baffle near its top portion said baffle having a least one perforation in its surface, and said housing having at least one perforation in the wall near its top portion; a fixed bed catalyst system supportably retained within said housing permitting both liquid and gas flow therethrough; and, an agitator shaft terminating in a turbine blade substantially adjacent the perforation in the wall of said housing, said agitator having a passageway including an opening in an upper portion thereof to the interior of an upper part of said tank and terminating in an opening adjacent the turbine blade.

Abstract: N-benzyl-m-phenylenediamine derivatives of general formula (I) or the physiologically tolerated, water-soluble salts thereof and dyeing agents for keratin fibers containing these compounds.

Abstract: The object of the invention are (p-aminohydroxyphenyl)acrylamide derivatives of general formula (I) or the physiologically tolerated, water-soluble salts thereof and oxidative coloring agents for keratin fibers, containing these compounds.

Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.

Abstract: Hydrogel polymer blends including precursors and crosslinked forms of the compositions. The blends provide an improved approach to achieve high quality, uniform coatings with better commercial viability than other approaches including copolymerization. Applications include mass spectral analysis of biomolecular analytes such as proteins. Dextran and acrylamide systems are preferred. Benzophenone groups can be used as photocrosslinking groups. Photoinitiators are not needed. Functionalities which can selectively bind to biomolecular analytes are included.

Abstract: This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.

Abstract: Substituted 1-aminobutane-3-ol compounds, methods for producing them, pharmaceutical compounds containing them, and the use of substituted 1-aminobutane-3-ol compounds for producing pharmaceutical compounds.

Abstract: The present invention is directed, in part, to fluorescent metal sensors for detecting metal ions, and methods of making and using the same.

Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

Abstract: The invention provides novel tetradentate enediyne ligands that are themselves thermally stable, yet react at about room temperature or slightly higher upon addition of metal ions or under photothermal conditions. In another aspect of the invention, a method of treating a disorder in a mammal comprising administering a therapeutically effective amount of a compound or composition is provided. In addition, the free ligand can be delivered to the mammal prior to complexation to metals, such that the ligand is exposed to a metal in the body and forms a metal complex in vivo. Furthermore, a metal complex of the invention can be administered to the mammal such that the complex exchanges the first metal center with another endogenous metal in order to form a second metal complex in vivo. The second metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions.

Abstract: This invention relates to improved polyepoxide resins cured with a mixture of methylene bridged poly(cycloaliphatic-aromatic)amines and a process for preparing such polyepoxide resins as well as to the methylene bridged poly(cycloaliphatic-aromatic)amine compositions and a method of making them. The improvement resides in using a curative (herein referred to as “Heavy MPCA”) comprised of the partially hydrogenated condensation product of formaldehyde and aniline or methyl substituted aniline containing a substantial amount (from 35 to 85% by weight, preferably 40 to 60% by weight) of oligomers in the form of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 aniline or methyl substituted aniline derivatives.

Abstract: The invention intends to provide means for producing halogenated aromatic methylamine useful as an intermediate in the production of agrochemical or medical preparations, by an industrially advantageous method. The process according to the present invention for producing halogenated aromatic methylamine is characterized by comprising hydrogen-reducing a halogenated aromatic nitrile represented by formula (1): (wherein X represents a chlorine atom or a fluorine atom, m represents an integer of 1 to 5, n represents an integer of 1 to 5, m+n?6, and when n is 2 or more, each X may be the same or different) using a hydrogenating catalyst in the presence of an organic acid in a solvent to produce a halogenated aromatic methylamine represented by formula (2): (wherein X, m and n have the same meanings as defined above, and a represents an integer of 1 to m).

Abstract: Materials for organic electroluminescence devices represented by following general formula [1]: wherein A represents a substituted or unsubstituted arylene group having 22 to 60 carbon atoms, X1 to X4 each independently represent a substituted or unsubstituted arylene group having 6 to 30 carbon atoms, X1 and X2 may be bonded to each other, X3 and X4 may be bonded to each other, Y1 to Y4 each independently represent an organic group represented by general formula [2], a to d each represent an integer of 0 to 2 and, when the arylene group represented by A has 26 or less carbon atoms, a+b+c+d>0 and the arylene group does not contain two or more anthracene nucleus; general formula [2] being: wherein R1 to R4 each independently represent hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 20 carbon atoms, cyano group or form a triple bond by a linkage of R1 and R2 or R3 and R4, Z represents a substituted or unsu

Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.

Abstract: The present invention relates to a novel process for preparing an aminostilbene derivative, which is important as an active component of anticancer drugs or an intermediate for preparation thereof, as well as methods of producing the same.

Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula wherein X, Z, X1, R1, R2, Ra, Rb, R3, R4 and Y are as defined in the specification.

Abstract: An organic luminescent device material, comprising an amine compound represented by the following formula (I): wherein R1, R2 and R3, which are the same or different, each represents an unsubstituted or substituted aryl group, an unsubstituted or substituted heterocyclic group or an unsubstituted or substituted aliphatic hydrocarbon group, provided that at least two among R1, R2 and R3 are each an unsubstituted or substituted aryl or heterocyclic group; or any two among R1, R2 and R3 combine with each other to complete a ring; provided that at least one among R1, R2 and R3 has a moiety represented by the following formula (II), wherein R4, R5 and R6 each represents a hydrogen atom or a substituent group, Z1 represents atoms forming a 5, 6 or 7-membered ring, and m represents 0, 1 or 2.

Abstract: Disclosed are multibinding compounds which are ?2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: The present invention relates to halogen-containing aromatic compounds and methods thereof. The present invention relates a halogen-containing aromatic acid dianhydride, halogen-containing aromatic tetranitrile compound, halogen-containing m-phenylenediamine compound and fluorine compound, and a method thereof.